Haplotype analysis suggest common founders in carriers of the recurrent <it>BRCA2 </it>mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families

Haplotype analysis suggest common founders in carriers of the recurrent <it>BRCA2 </it>mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families

<p>Abstract</p> <p>Background</p> <p>The 3398delAAAAG mutation in <it>BRCA2 </it>was recently found to recur in breast and/or ovarian cancer families from the French Canadian population of Quebec, a population that has genetic attributes consistent with a fo...

Full description

Bibliographic Details
Main Authors:	Foulkes William D, Mes-Masson Anne-Marie, Shen Zhen, Perret Chantal, Arcand Suzanna L, Leblanc Guy, Oros Kathleen K, Ghadirian Parviz, Provencher Diane, Tonin Patricia N
Format:	Article
Language:	English
Published:	BMC 2006-03-01
Series:	BMC Medical Genetics
Online Access:	http://www.biomedcentral.com/1471-2350/7/23

Similar Items

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
by: Supriya Behl, et al.
Published: (2020-04-01)

The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
by: Paulina M Wojnarowicz, et al.
Published: (2012-01-01)

Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic <i>BRCA1</i> Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic <i>BRCA1</i> and <i>BRCA2</i> Variants
by: Wejdan M. Alenezi, et al.
Published: (2022-04-01)

Founder mutations in <it>BRCA1/2 </it>are not frequent in Canadian Ashkenazi Jewish men with prostate cancer
by: Kotar Kimberley, et al.
Published: (2003-08-01)

Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
by: Ashley H Birch, et al.
Published: (2011-01-01)

Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer
by: Stavros Glentis, et al.
Published: (2019-10-01)

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
by: J. Maksimenko, et al.
Published: (2018-06-01)

Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
by: Jaco Oosthuizen, et al.
Published: (2021-02-01)

Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.
by: Laura Caleca, et al.
Published: (2014-01-01)

BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
by: Angela R. Solano, et al.
Published: (2018-08-01)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
by: Tomasz Kluz, et al.
Published: (2018-02-01)

The <it>BRCA1 </it>Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies
by: Zhang Jinghui, et al.
Published: (2007-10-01)

BRCA1 and BRCA2 and Inherited Predisposition to Breast and Ovarian Cancers
by: Patricia N. Tonin
Published: (2002-12-01)

Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects
by: Ana Peixoto, et al.
Published: (2020-07-01)

Haplotype variation in founders of the <em>Mauremys annamensis</em> population kept in European Zoos
by: Barbora Somerova, et al.
Published: (2015-06-01)

BRCA1 4153delA founder mutation in Russian ovarian cancer patients
by: Krylova Nadezhda, et al.
Published: (2006-09-01)

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study.
by: Artur Kowalik, et al.
Published: (2018-01-01)

Characterization of three new serous epithelial ovarian cancer cell lines
by: Hébert Josée, et al.
Published: (2008-05-01)

The Features of BRCA1 and BRCA2 Germline Mutations in Hakka Ovarian Cancer Patients: BRCA1 C.536 A>T Maybe a Founder Mutation in This Population
by: Luo Y, et al.
Published: (2022-03-01)

Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity
by: Rong Bu, et al.
Published: (2023-11-01)

Investigation into the origins of an ancient BRCA1 founder mutation identified among Chinese families in Singapore
by: Shaw, Tarryn, et al.
Published: (2021)

Ran GTPase: A Key Player in Tumor Progression and Metastasis
by: Zied Boudhraa, et al.
Published: (2020-05-01)

The Genetic and Molecular Analyses of <i>RAD51C</i> and <i>RAD51D</i> Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population
by: Wejdan M. Alenezi, et al.
Published: (2022-04-01)

BRCA1/2 potential founder variants in the Jordanian population: an opportunity for a customized screening panel
by: Olfat Ahmad, et al.
Published: (2023-07-01)

BRCA mutations: screening for germ-line founder mutations among early-onset Syrian breast cancer patients
by: Salma Wahabi Alzahabi, et al.
Published: (2024-02-01)

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
by: Jun Li, et al.
Published: (2021-05-01)

Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
by: Veronica Fragoso-Ontiveros, et al.
Published: (2019-01-01)

An essential role for Ran GTPase in epithelial ovarian cancer cell survival
by: Provencher Diane M, et al.
Published: (2010-10-01)

Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer
by: Seyed Mohsen Miresmaeili, et al.
Published: (2016-04-01)

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
by: Dolores Gallardo-Rincón, et al.
Published: (2022-06-01)

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
by: Suspitsin Evgeny N, et al.
Published: (2009-02-01)

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
by: Jun Li, et al.
Published: (2022-01-01)

The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer
by: Nerina C. van der Merwe, et al.
Published: (2020-05-01)

Haplotype analysis reveals a possible founder effect of RET mutation R114H for Hirschsprung's disease in the Chinese population.
by: Belinda K Cornes, et al.
Published: (2010-01-01)

Population genetic structure of Etroplus suratensis Bloch, 1790 in South India: preliminary evidence of founder haplotypes shared among populations
by: Shanmugam Chandrasekar, et al.
Published: (2019-09-01)

The <i>BRCA1</i> c.4096+1G>A Is a Founder Variant Which Originated in Ancient Times
by: Paolo Aretini, et al.
Published: (2023-10-01)

Prevalence of the <it>BRCA1 </it>founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome
by: Ewald Ingrid P, et al.
Published: (2011-12-01)

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines
by: Provencher Diane M, et al.
Published: (2008-08-01)

Founder influences on the development of organizations: A comparison between founder and non‐founder managed Russian firms
by: Russia V. Shirokova, et al.
Published: (2008-06-01)

Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer
by: Anna P. Sokolenko, et al.
Published: (2023-02-01)